These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review). Gehrig S, Efferth T. Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846 [Abstract] [Full Text] [Related]
4. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis. Wenzler T, Yang S, Braissant O, Boykin DW, Brun R, Wang MZ. Antimicrob Agents Chemother; 2013 Nov; 57(11):5330-43. PubMed ID: 23959303 [Abstract] [Full Text] [Related]
5. The phenomenon of treatment failures in Human African Trypanosomiasis. Brun R, Schumacher R, Schmid C, Kunz C, Burri C. Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845 [Abstract] [Full Text] [Related]
9. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-alpha-difluoromethylornithine (DFMO). Iten M, Matovu E, Brun R, Kaminsky R. Trop Med Parasitol; 1995 Sep; 46(3):190-4. PubMed ID: 8533023 [Abstract] [Full Text] [Related]
10. [Melarsoprol]. Simon F. Med Trop (Mars); 1999 Sep; 59(4):331-2. PubMed ID: 10816741 [No Abstract] [Full Text] [Related]
11. Veterinary link to drug resistance in human African trypanosomiasis? Barrett MP. Lancet; 2001 Aug 25; 358(9282):603-4. PubMed ID: 11530144 [No Abstract] [Full Text] [Related]
12. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Alibu VP, Richter C, Voncken F, Marti G, Shahi S, Renggli CK, Seebeck T, Brun R, Clayton C. Mol Biochem Parasitol; 2006 Mar 25; 146(1):38-44. PubMed ID: 16343658 [Abstract] [Full Text] [Related]
13. Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistance. Bernhard SC, Nerima B, Mäser P, Brun R. Int J Parasitol; 2007 Nov 25; 37(13):1443-8. PubMed ID: 17602691 [Abstract] [Full Text] [Related]
14. Evaluation of the micro-CATT, CATT/Trypanosoma brucei gambiense, and LATEX/T b gambiense methods for serodiagnosis and surveillance of human African trypanosomiasis in West and Central Africa. Truc P, Lejon V, Magnus E, Jamonneau V, Nangouma A, Verloo D, Penchenier L, Büscher P. Bull World Health Organ; 2002 Nov 25; 80(11):882-6. PubMed ID: 12481210 [Abstract] [Full Text] [Related]
15. [The return of sleeping sickness in an epidemic form: international action for drugs]. Kager PA. Ned Tijdschr Geneeskd; 2002 Dec 28; 146(52):2527-30. PubMed ID: 12532663 [Abstract] [Full Text] [Related]
18. [Three patients with African sleeping sickness following a visit to Tanzania]. Mendonça Melo M, Rasica M, van Thiel PP, Richter C, Kager PA, Wismans PJ. Ned Tijdschr Geneeskd; 2002 Dec 28; 146(52):2552-6. PubMed ID: 12532670 [Abstract] [Full Text] [Related]
19. Chimerization at the AQP2-AQP3 locus is the genetic basis of melarsoprol-pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates. Graf FE, Baker N, Munday JC, de Koning HP, Horn D, Mäser P. Int J Parasitol Drugs Drug Resist; 2015 Aug 28; 5(2):65-8. PubMed ID: 26042196 [Abstract] [Full Text] [Related]
20. In vitro drug sensitivity of Trypanosoma gambiense isolates. Brun R, Baeriswyl S, Kunz C. Acta Trop; 1989 Oct 28; 46(5-6):369-76. PubMed ID: 2575872 [Abstract] [Full Text] [Related] Page: [Next] [New Search]